Abstract
Purpose
Knowledge of the different usage patterns that emerge during a long-term statin therapy is limited. The aim of this study was to characterize statin use, including the rates of reinitiation after extended periods of non-use, transitions between good and poor adherence, and the effect of the length of a drug-free period on the identification of new users.
Methods
The study cohort comprised individuals aged 45–84 years who were identified in the Finnish prescription register as having purchased statins between 1997 and 2007. New users in 1997, including those with no statin purchases during the preceding 3 years, were followed-up until institutionalization, death, or 31 December 2007. Reinitiation rates after ≥180 days with no refill for statins were analyzed using survival analysis. Annual adherence levels and the prevalences of good (proportion of days covered ≥0.80) and poor (<0.80) adherence were calculated for ten 1-year periods following initiation. For statin users in 2007, purchases were captured over the previous 10 years.
Results
Based on the data extracted from the Finnish prescription register, 32,760 persons initiated statin treatment in 1997, of whom 48.1% had discontinued it for at least 180 days by the end of the follow-up period. Of the discontinuers, 46.7% restarted the treatment within 1 year and 88.7% by the end of the follow-up. Of those followed up for ≥10 years, 51.8% had ≥6 years of treatment with good adherence. In 2007, 27.7% of the initiators having no statin purchases within the previous year had refills during the preceding 10 years.
Conclusion
Statin use is dynamic. This should be taken into consideration in clinical practice and when studying the incidence, patterns, and health outcomes of statin use.
Similar content being viewed by others
References
Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 366:1267–1278
Brugts JJ, Yetgin T, Hoeks SE et al (2009) The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. Br Med J 338:b2376
Shalev V, Chodick G, Silber H et al (2009) Continuation of statin treatment and all-cause mortality. Arch Intern Med 169:260–268
Perreault S, Dragomir A, Blais L et al (2009) Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol 65:1013–1024
Corrao G, Conti V, Merlino L et al (2010) Results of retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily practice in Italy. Clin Ther 32:300–310
Benner JS, Glyn RJ, Mogun H et al (2002) Long-term persistence in use of statin therapy in elderly patients. JAMA 288:455–461
Mantel-Teeuwisse AK, Goettsh WG, Klungel OH et al (2004) Long term persistence with statin treatment in daily medical practice. Heart 90:1056–1066
Perreault S, Blais L, Lamarre D et al (2005) Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 59:564–573
Helin-Salmivaara A, Lavikainen P, Korhonen MJ et al (2008) Long-term persistence with statin therapy: a nation-wide register study. Clin Ther 30(pt 2):2228–2240
Helin-Salmivaara A, Lavikainen P, Korhonen MJ et al (2010) Pattern of statin use among 10 cohorts of new users from 1995 to 2004: a register-based nationwide study. Am J Manag Care 16:116–122
Risselada R, Straatman H, van Kooten F et al (2009) Withdrawal of statins and risk of subarachnoid hemorrhage. Stroke 40:2887–2892
Daskapoulou SS, Delaney JA, Fillion KB et al (2008) Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J 79:2083–2091
Pineda A, Cubeddu LX (2010) Statin rebound or withdrawal syndrome: does it exist? Curr Athreoscler Rep 13:23–30
Hudson M, Rahme E, Richard H et al (2007) Comparison of measures of medication persistency using a prescription drug database. Am Heart J 153:59–65
Brookhart MA, Patrick AR, Schneeweiss S et al (2007) Physician follow-up and provider continuity are associated with long-term medication adherence. Arch Intern Med 167:847–852
Ray WA (2003) Evaluating medication effects outside clinical trials: new-user designs. Am J Epidemiol 158:915–920
Scranton RE, Young M, Lawler E et al (2005) Statin use and fracture risk. Arch Intern Med 165:2007–2012
Willke RJ, Zhou S, Vogel RA (2008) Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience. Curr Med Res Opin 24:2873–2882
Smeeth L, Douglas I, Hall AJ et al (2008) Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 67:99–109
Chodick G, Heymann AD, Flash S et al (2010) Persistence with statins and incident cataract: a population-based historical cohort study. Ann Epidemiol 20:136–142
Furu K, Wettermark B, Andersen M et al (2009) The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 106:86–94
Peura S, Raijaniemi S, Kurkijärvi U. Pharmaceutical Pricing and Reimbursement Information Project. Finland 2007. Available at: http://ppri.oebig.at/Downloads/Results/Finland_PPRI_2007.pdf. Accessed 1 Feb, 2010
Martikainen JE, Saastamoinen LK, Korhonen MJ et al (2010) Impact of restricted reimbursement on the use of statins in Finland. A register-based study. Med Care 48:761–766
World Health Organization (WHO). About the ATC/DDD system. Available at: http://www.whocc.no/atcddd/ . Accessed 1 Feb, 2010
Andrade SE, Kahler KH, Frech F et al (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15:565–574
Simpson S, Eurich D, Majumdar S et al (2006) A meta-analysis of the association between adherence to drug therapy and mortality. Br Med J 333(7557):15
Hippisley-Cox J, Coupland C (2010) Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. Br Med J 340:c2197. doi:10.1136/bmj.c2197
Schneeweiss S, Patrick AR, Maclure M et al (2007) Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation 115:2128–2135
Dormuth C, Scneeweiss S, Brookhart A et al (2007) Factors related to splitting tablets of HMG-CoA reductase inhibitors: a population based analysis in British Columbia. Pharmacoepidemiol Drug Saf 16:5137
Steiner JF (2010) Can we identify clinical predictors of medication adherence....and should we? Med Care 48:193–195
Acknowledgments
We thank Kristiina Tyrkkö and Hilkka Ruuska of the SII for their expertise in extracting and managing the administrative data. This study was funded by a grant (October 26, 2007) from the Social Insurance Institution (SII) of Finland (Maarit Jaana Korhonen and Arja Helin-Samivaara).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Korhonen, M.J., Helin-Salmivaara, A. & Huupponen, R. Dynamics of long-term statin therapy. Eur J Clin Pharmacol 67, 925–931 (2011). https://doi.org/10.1007/s00228-011-1019-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-011-1019-2